Results 51 to 60 of about 839,337 (241)

GNB3 c.825c>T polymorphism influences T-cell but not antibody response following vaccination with the mRNA-1273 vaccine

Frontiers in Genetics, 2022
Background: Immune responses following vaccination against COVID-19 with different vaccines and the waning of immunity vary within the population. Genetic host factors are likely to contribute to this variability.
Ieva Čiučiulkaitė, B. Möhlendick, Laura Thümmler, Neslinur Fisenkci, C. Elsner, U. Dittmer, W. Siffert, M. Lindemann   +7 more
semanticscholar   +1 more source

Effectiveness of BNT162b2 and mRNA-1273 Vaccines against COVID-19 Infection: A Meta-Analysis of Test-Negative Design Studies

Vaccines, 2022
Although numerous COVID-19 vaccines are effective against COVID-19 infection and variants of concern (VOC) in the real world, it is imperative to obtain evidence of the corresponding vaccine effectiveness (VE).
Shuailei Chang, Hongbo Liu, Jian Wu, Wenwei Xiao, Sijia Chen, Shaofu Qiu, Guangcai Duan, Hongbin Song, Rongguang Zhang   +8 more
doaj   +1 more source

Local and Systemic Adverse Reactions to mRNA COVID-19 Vaccines Comparing Two Vaccine Types and Occurrence of Previous COVID-19 Infection [PDF]

, 2021
The aim of this study was to assess adverse reactions to COVID-19 vaccines, comparing the BNT162b2 or the mRNA-1273 COVID-19 vaccines and the presence and seriousness of a previous COVID-19 infection.
Aguilera, Cristina, Agustí Escasany, M. Antònia, Borras Bermejo, Blanca, Campins Martí, Magda, Cossio, Yolima, Martínez Gómez, Xavier, Otero-Romero, Susana, Parés-Badell, Oleguer, Pinós Tella, Laia, Rodrigo-Pendás, José Ángel, Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i de Medicina Preventiva i Salut Pública, Uriona, Sonia   +11 more
core   +1 more source

Prevention and Attenuation of COVID-19 by BNT162b2 and mRNA-1273 Vaccines

medRxiv, 2021
BACKGROUND: Information is limited on messenger RNA (mRNA) BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccine effectiveness (VE) in preventing SARS-CoV-2 infection or attenuating disease when administered in real-world conditions ...
M. Thompson, J. Burgess, A. Naleway, Harmony L. Tyner, Sarang K. Yoon, J. Meece, Lauren E. W. Olsho, A. Caban-Martinez, A. Fowlkes, K. Lutrick, H. Groom, K. Dunnigan, M. Odean, K. Hegmann, Elisha L Stefanski, Laura J. Edwards, Natasha Schaefer-Solle, L. Grant, K. Ellingson, J. Kuntz, Tnelda Zunie, M. Thiese, L. Ivacic, Meredith G. Wesley, Julie Mayo Lamberte, Xiaoxiao Sun, Michael E. Smith, Andrew L. Phillips, Kimberly D. Groover, Young M. Yoo, J. Gerald, Rachel T. Brown, Meghan K Herring, G. Joseph, S. Beitel, Tyson Morrill, Josephine Mak, Patrick Rivers, Brandon Poe, Brian Lynch, Yingtao Zhou, Jing Zhang, Anna Kelleher, Yan Li, Monica Dickerson, Erika N Hanson, Kyley Guenther, S. Tong, A. Bateman, E. Reisdorf, J. Barnes, E. Azziz‐Baumgartner, D. Hunt, Melissa L. Arvay, P. Kutty, A. Fry, M. Gaglani   +56 more
semanticscholar   +1 more source

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5

Nature Communications, 2023
In this study, the authors estimate the effectiveness of the mRNA-1273 (Moderna) vaccine for Omicron subvariants using data from the USA on ~31,000 cases and ~92,000 matched controls.
H. Tseng, B. Ackerson, K. Bruxvoort, L. Sy, J. Tubert, Gina S. Lee, J. Ku, A. Florea, Yi Luo, S. Qiu, S. Choi, H. Takhar, Michael Aragones, Y. Paila, S. Chavers, C. Talarico, L. Qian   +16 more
semanticscholar   +1 more source

mRNA-1273 [PDF]

Reactions Weekly, 2022
  +11 more sources

Adverse Effects of Third-Dose Moderna Vaccination for Healthcare Workers of Udayana University Hospital, Bali, Indonesia [PDF]

, 2022
. Background Since its first sighting in China at the end of 2019, COVID-19 had spread rapidly around the world, with no exception, to Indonesia. World Health Organization officially declared COVID-19 as a pandemic in March 2020.
Cokorda Agung Wahyu Purnamasidhi, Darren Junior, Dewa Ayu Fony Prema Shanti, Giovanca Verentzia Purnama, I Gede Purna Weisnawa, I Komang Hotra Adiputra, Jerry, Putu Kintan Wulandari, Richard Christian Suteja   +8 more
core   +2 more sources

Serological response after COVID-19 mRNA-1273 booster dose in immunocompromised patients, Taiwan, July to August 2021

Journal of the Formosan Medical Association, 2022
Background: Whether immunocompromising conditions affect the immunogenicity of COVID-19 booster vaccination remains a concern, which impedes the vaccination campaign in people most vulnerable to COVID-19-associated morbidity and mortality.
Kuan-Yin Lin, Ming-Ju Hsieh, Sui-Yuan Chang, Si-Man Ieong, Chien-Yu Cheng, Wang-Huei Sheng, Shan-Chwen Chang   +6 more
doaj   +1 more source

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness [PDF]

, 2020
A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the coronavirus disease 2019 (COVID-19) global pandemic.
Abiona, O.M., Altaras, N.E., Alvarado, G.S., Bahl, K., Baric, R.S., Bennett, H., Bock, K.W., Boyoglu-Barnum, S., Carfi, A., Chang, L.A., Chappell, J.D., Corbett, K.S., Denison, M.R., Dinnon, K.H., DiPiazza, A.T., Doria-Rose, N.A., Edwards, D.K., Elbashir, S.M., Fritch, E.J., Garcia-Dominguez, D., Gillespie, R.A., Graham, B.S., Gully, K.L., Henry, C., Himansu, S., Hutchinson, G.B., Kong, W.-P., Leist, S.R., Leung, K., Liu, C., Loomis, R.J., Louder, M.K., Ma, L.Z., Martinez, D.R., Mascola, J.R., McLellan, J.S., Metkar, M., Minai, M., Moore, I.N., Morabito, K.M., Nagata, B.M., Narayanan, E., Nason, M.C., Phung, E., Presnyak, V., Renzi, I., Ruckwardt, T.J., Schmidt, S.D., Schäfer, A., Shaw, C.A., Shi, W., Stevens, L.J., Stewart-Jones, G., Wang, L., Wang, N., West, A., Woods, A., Wrapp, D., Wu, K., Yang, E.S., Zhang, Y., Ziwawo, C.T.   +61 more
core   +2 more sources

Analysis of the adverse events following the mRNA-1273 COVID-19 vaccine [PDF]

, 2023
OBJECTIVE: This study aims to characterize the adverse events (AEs) following the administration of the mRNA-1273 COVID-19 vaccine from the Vaccine Adverse Event Reporting System (VAERS) data.METHODS: In this case/non-case analysis, reports between 1 ...
Nishtala, Prasad S, Shabu, Angel
core   +1 more source